Isomorphic Labs and MSD team up to design cancer drugs with AI

Nov 19, 2026
Isomorphic will design small molecule candidates against an oncology target, with an upfront payment, milestones and royalties from MSD.

Isomorphic Labs, the AI drug design company led by chief executive Demis Hassabis, has signed a research collaboration with MSD, the trade name of Merck & Co., to discover small molecule drug candidates against an oncology target of strategic importance.

Isomorphic Labs will make in silico predictions and deliver molecular designs using its proprietary drug design engine, IsoDDE, drawing on select high-quality data sets supplied by MSD for the project. MSD will handle preclinical and clinical development, manufacturing and commercialisation of any resulting products.

Isomorphic Labs will receive an upfront payment and is eligible for payments tied to research, development, regulatory and commercial milestones, plus tiered royalties on net sales. It also gets an option to co-fund development in return for higher royalties. The companies did not disclose the payment amounts.

"The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions," said George Addona, who heads discovery, preclinical development and translational medicine at MSD Research Laboratories, according to the announcement. The deal follows Isomorphic's $5 billion Series C.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly, AI in Europe or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.